Posted by AGORACOM-JC
at 8:05 AM on Tuesday, January 19th, 2021
Pierre Bou-Mansour is former COO of LifeLabs, one of Canada’s largest medical service companies
Announced the expansion of its leadership team with the appointment of Pierre Bou-Mansour, P.Eng., to the role of Chief Operating Officer.
Effective immediately, Mr. Bou-Mansour will assume responsibility for ensuring operational excellence as Novamind develops its network of clinics, retreats, and research sites in 2021 and beyond.
Most recently, he served as the Chief Laboratory Operations Officer of Public Health Ontario, serving Canada’s largest province with over 14 million residents.
In this role, Bou-Mansour successfully led the expansion of Public Health Ontario’s testing capacity for the COVID-19 response.
TORONTO, ON / January 19, 2021 / Novamind Inc., (CSE:NM) (“Novamind” or the “Company”) a mental health company specialized in psychedelic medicine, announces the expansion of its leadership team with the appointment of Pierre Bou-Mansour, P.Eng., to the role of Chief Operating Officer. Effective immediately, Mr. Bou-Mansour will assume responsibility for ensuring operational excellence as Novamind develops its network of clinics, retreats, and research sites in 2021 and beyond.
An accomplished senior executive and leader, Pierre brings a wealth of experience managing large and complex healthcare organizations. Most recently, he served as the Chief Laboratory Operations Officer of Public Health Ontario, serving Canada’s largest province with over 14 million residents. In this role, Bou-Mansour successfully led the expansion of Public Health Ontario’s testing capacity for the COVID-19 response.
Pierre Bou-Mansour said, “Novamind’s Cedar Psychiatry clinics and Cedar Clinical Research sites are both well-positioned to scale as regulated access to psychedelic medicine continues to expand rapidly in jurisdictions around the world. I look forward to working with the leadership team to ensure strategic expansion of our operating model for clinical care and clinical research in psychedelic medicine.”
Pierre has a proven track record for growing and transforming healthcare companies. He spent eight years at LifeLabs, serving as the COO from 2017 to 2019, and successfully led the integration of two acquired competitors. During this period, LifeLabs grew into one of the largest medical service companies in Canada, with over 5,700 employees, 370 patient access sites, and over US $977 million in annualized revenue (dnb.com).
Yaon Conforti, Chief Executive Officer and Director of Novamind added, “Pierre brings a distinguished operational track record in healthcare to drive the expansion of Novamind’s network of mental health clinics and clinical research sites. His role is critical as we execute against our pipeline of growth opportunities.”
Posted by AGORACOM-JC
at 8:34 AM on Monday, January 18th, 2021
Entered into a technology purchase agreement with DEFSEC Corporation to acquire a proprietary non-lethal munitions technology system referred to as the Low Energy Cartridge technology
The LEC Technology is a proprietary non-lethal cartridge-based ordnance system.
DEFSEC is an Ottawa-based based private company owned by David Luxton the Executive Chairman of KWESST.
Ottawa, Ontario–(January 18, 2021) – KWESST Micro Systems Inc. (TSXV: KWE) (“KWESST” or “the Company”) today announced it has entered into a technology purchase agreement (the “Purchase Agreement”) with DEFSEC Corporation (“DEFSEC”) to acquire a proprietary non-lethal munitions technology system referred to as the Low Energy Cartridge technology (“LEC Technology”). The LEC Technology is a proprietary non-lethal cartridge-based ordnance system. DEFSEC is an Ottawa-based based private company owned by David Luxton the Executive Chairman of KWESST.
“We see the LEC Technology as having universal application across four market segments that currently use a variety of dated “non-lethal” or “less-lethal” products, each having a vast global market. These segments are (i) public order (riots and control of dangerous subjects), (ii) military and law enforcement training (realistic force-on-force training), (iii) personal defence (home, car, boat, RV, camping, hiking), and (iv) high-action gaming,” said Jeff MacLeod, KWESST Founder and CEO. “The kind of fatalities that have led to widespread protests in the U.S. are just one example of the need for more advanced solutions that enable law enforcement to engage with more benign devices from a safer stand-off distance and ensure that everyone goes home alive.”
The market development of the LEC Technology will benefit from the deep combined experience of Jeff MacLeod and David Luxton in the specialty ordnance business. Mr. MacLeod is a highly knowledgeable defence industry executive with over 20 years’ experience in the field of small arms and advanced soldier systems. Prior to establishing KWESST, he was the General Manager of Colt Canada, the primary supplier of small arms to the Canadian military. David Luxton was the founder in 1990 of Simunition Inc., a business that develops and sells simulated munitions for realistic close quarters combat training for military and law enforcement around the world. He sold the business to a large military contractor and from 2015 – 2018 he was the Executive Chairman of United Tactical Systems LLC, a U.S. company that develops and sells products for the global less-lethal market.
Posted by AGORACOM-JC
at 7:26 AM on Monday, January 18th, 2021
Completed its exhaustive due diligence review and corporate integration documentation and expects delivery of final legal opinions in relation to the proposed acquisition of Prego International Group AS.
ZeUPay will be fully integrated into the Mula ecosystem.
Users of ZeU and the Mula platform native function and applications, as well as users of third-party developed applications, will be able to use its Crypto to Fiat gateway functionalities.
Montréal– January 17, 2021 –ZeU Technologies Inc.(CSE:ZEU)(CNSX:ZEU.CN) is pleased to announce that it has completed its exhaustive due diligence review and corporate integration documentation and expects delivery of final legal opinions in relation to the proposed acquisition of Prego International Group AS.
Management of both companies plan to sign the final acquisition documents later this week. It is expected that all regulatory review should be completed on or around February 5, 2021. At that point, all shares of Prego International would have been exchanged for convertible debentures of ZeUPay, a wholly owned subsidiary of ZeU Technologies and the target corporation.
Ronald Eriksen will join the board of directors of ZeU Technologies at closing.
ZeUPay will be fully integrated into the Mula ecosystem. Users of ZeU and the Mula platform native function and applications, as well as users of third-party developed applications, will be able to use its Crypto to Fiat gateway functionalities. All current account holders of Prego, including Pay2Go card holders, will be seamlessly migrated to a Mula digital wallet that will allow them to send or receive money, lend to the ecosystem, earn income and interest, and structure transactions. ZeUPay’s utility token will be hot-swappable with a range of other tokens, including the MulaPay stable utility token.
Posted by AGORACOM-JC
at 7:14 AM on Monday, January 18th, 2021
Frederic Fasano named President and COO
Steve Saviuk continues as CEO and becomes Vice-Chairman of the Board of Directors
MONTREAL , Jan. 18, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, announced today the appointment of Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer, effective January 18th , to augment its senior leadership team and support expansion of Valeo’s commercial activities. Mr. Fasano has also been elected to the Company’s Board of Directors effective as of today.
“It gives me true pleasure to welcome Frederic to the Valeo executive team in this important new role. He possesses extensive International pharmaceutical experience and his management skills are well suited to helping us build a leading innovative pharmaceutical company with a deep commitment to our selected therapeutic areas of focus”, said Steve Saviuk, CEO. “This increase in management depth, coupled with our solid foundation of products and people, positions us well for the dynamic growth we foresee in the coming years.”
When we look back at 2020 this time next year … what we’ve done is very little in my opinion to date.”
Wait … What?
“This year (2021) will see major growth and expansion …. We’re about to reap the rewards from all the groundwork and that is exciting to me … This will be our biggest year by a country mile”
Given the fact we had to do this interview on a Sunday due to Anson “putting in 100 work weeks” and “18-20 Zoom presentations per day”, as well as, 4 pretty significant press releases in the first 2 weeks of 2021, Anson is living up to his word.
Moreover, in this interview, he shows no hesitation when asked if he still feels the same way about 2021.
Watch this great Sunday morning interview with Loop Insights Founder and CEO, Rob Anson.
Posted by AGORACOM-JC
at 12:14 PM on Thursday, January 14th, 2021
Commercial launch to impact first half 2021 revenue
$30 million forecasted annual peak sales
8 years of proven in-market safety Internationally
Low molecular weight heparin increasingly used to prevent COVID-19 driven complications
“The regulatory approval of Redesca is a significant corporate milestone for Valeo and also great news for the Canadian healthcare system. Mandatory use of biosimilars is increasingly being adopted across the country and is expected to help provide significant savings to provincial healthcare plans”, said Steve Saviuk , President and CEO. “With more than 8 years of proven in-market safety internationally and a robust supply chain ensuring product availability, we expect Redesca to play a major role in the achievement of our growth objectives”.
Posted by AGORACOM
at 7:23 PM on Wednesday, January 13th, 2021
WHY SOBRSafe?
“Nearly 50% of industrial injuries and fatalities are alcohol related. Commercial Fleets suffer from over 11,000 alcohol related accidents every year. That rate is climbing and technology has failed to keep pace with this epidemic”
SOBRsafe has developed a patented, touch-based alcohol detection system for truck fleets, school bus fleets and industrial workplaces named SOBR Check™
SOBRSafe mission is to prevent alcohol-related injuries and deaths on our roadways and workplaces through the simple touch of a finger. This results in increased productivity and profitability.
Save lives
Increases productivity
Creates significant economic benefits
Protects the health of employees
Watch these short but powerful videos demonstrating how SOBR Check™ will be applied across different verticals.
Technology Overview: Introducing SOBR Safe
https://youtu.be/GGzkkBCUt_A
School Buses: Drunk Driving Preventative Technology
https://youtu.be/7DS2tRyC-xM
Safety of the school children #1 priority
Identifying Bus Driver Intoxication
Realtime sobriety detection
Wirelessly communicates offenders to dispatch
Realtime sobriety detection technology
Beta Stage technology to be made available to schools nationwide
FEATURES:
User data is recorded in seconds, measuring humidity, barometric sensors, and temperature to provide accuracy and consistency across multiple applications and environments
The user data is sent to SOBRSafe’s Global Cloud Platform allowing managers to receive immediate notification of test results and immediate action; providing safety to employees and employer through the touch of a finger.
Transdermal Sensor
Alcohol detection with efficient workflow, non-invasive “go/no go” functionality, results in seconds
Biometric Identification
Alcohol scan results tied to a unique fingerprint ID, preventing circumvention, enhancing security
Real-Time Management
Wireless delivery of enterprise-wide data to central dashboard for immediate corrective action
Predictive Analytics
Actionable data collection empowers reduced-risk modeling, potentially lowering insurance costs
Preventative Solution
SOBRSafe® gets ahead of the risk, helping eliminate alcohol on the shop floor, behind the wheel
FULL DISCLOSURE: SOBR Safe is an advertising client of AGORA Internet Relations Corp
Posted by AGORACOM-JC
at 9:28 AM on Wednesday, January 13th, 2021
Announced that the Company has started the process of preparing for a listing of its common shares on the NASDAQ Capital Market
Company has engaged a New York based investment bank to begin the NASDAQ listing process.
The NASDAQ is a mark of achievement and stature for qualified companies.
Listed companies must meet financial and liquidity requirements and satisfy corporate governance and disclosure requirements on both an initial and continuing basis.
Los Angeles, CA., Jan. 13, 2021 — Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer and systems developer, today announced that the Company has started the process of preparing for a listing of its common shares on the NASDAQ Capital Market (“NASDAQ”).
The Company has engaged a New York based investment bank to begin the NASDAQ listing process. The NASDAQ is a mark of achievement and stature for qualified companies. Listed companies must meet financial and liquidity requirements and satisfy corporate governance and disclosure requirements on both an initial and continuing basis.
The listing of the Company’s common shares on the NASDAQ is subject to the approval of the NASDAQ and the ability of the Company to satisfy all applicable listing and regulatory requirements. While the Company intends to satisfy all of the applicable listing criteria, there is no assurance that the NASDAQ will approve the Company’s application or that the Company will complete the listing as proposed.
Draganfly management believes up-listing to NASDAQ will:
Provide additional opportunities to attract institutional and retail investors, allowing the Company to broaden its investor base in the United States and internationally.
Increase the visibility of the Company, its growth strategy, accomplishments and results to date.
Embark on an aggressive M&A strategy.
Increase liquidity of the Company’s common shares; and
Raise the Company’s overall profile and ultimately enhance shareholder value.
“Today’s announcement is a significant milestone in our efforts to build Draganfly into an industry-leading manufacturer and systems developer,” said Cameron Chell, CEO of Draganfly. “In addition to increasing our visibility in the marketplace, the up-listing should improve the liquidity of our stock, broaden our institutional shareholder base and augment long-term shareholder value.”
Draganfly had significant growth in 2020 in regard to its customer acquisitions, partnerships, product development and the growth of the Company’s sales pipeline. Here are some highlights from the past twelve months:
Launched the Vital Intelligence Smart Vital COVID-19 assessment platform that can automatically detect elevated body temperature and, with voluntary consent, heart rate, respiratory rate and O2 saturation, all from a camera that takes seconds to capture the information.
Launched a telehealth app for third party developers to integrate the Smart Vital technology with their own apps and devices.
Achieved 200%+ year-over-year revenue growth with 50% quarter-over-quarter revenue growth in the third quarter (1) ;
Launched two additional flight services divisions in the mining and facility management industries (which includes providing the delivery via Draganfly’s patented drone technologies of the Varigard pathogen and virus surface sanitizer);
Exclusive worldwide distributor of Aerovironment’s (NASDAQ: AVAV) Quantix Mapper RPAS;
Selected by Coldchain Technology Services, LLC to immediately develop and provide flight services of a robust vaccine delivery payload for use in critical regions for drone delivery of the COVID-19 vaccine; and
Awarded new patent for a vertical take-off and landing (VTOL) cargo delivery drone with variable center of gravity.
Posted by AGORACOM-JC
at 8:07 AM on Wednesday, January 13th, 2021
Granted, and registered a Canadian patent (Registration No.: 2,898,980).
The patent claims cover the formulation composition for use in an infant and/or toddler formulation.
Else, which already holds a worldwide patent covering its 100% plant-based toddler and infant formulas, has just received a grant notice from the Canadian Patent Office on the composition of its proprietary formulation, for use in a non-dairy infant and/or toddler formula.
The patented composition provides the necessary proteins, amino-acids and other nutrients needed in a single food serving for a whole balanced nutrition.
VANCOUVER, BC , Jan. 13, 2021 – ELSE NUTRITION HOLDINGS INC. (BABY.V) (BABYF) (0YL.F) (“Else” or the “Company”) the plant-based baby, toddler and children nutrition company , is pleased to update that it has been granted, and registered a Canadian patent (Registration No.: 2,898,980). The patent claims cover the formulation composition for use in an infant and/or toddler formulation.
Else, which already holds a worldwide patent covering its 100% plant-based toddler and infant formulas, has just received a grant notice from the Canadian Patent Office on the composition of its proprietary formulation, for use in a non-dairy infant and/or toddler formula. The patented composition provides the necessary proteins, amino-acids and other nutrients needed in a single food serving for a whole balanced nutrition.
“The growth of our intellectual property portfolio in the Canadian market is timely as we get set to expand our North American presence,” stated Hamutal Yitzhak , CEO and Co-Founder of Else Nutrition. “Our Plant-Based formulation has functional and meaningful applications to a wide range of potential consumer markets. While we remain laser-focused on the launch of our baby products, our IP can also help serve the rapidly growing $3 billion plant-based food market in Canada , giving consumers, nutritious Clean Label, whole food-based offerings,” she added.”
